In adults with obesity treated in routine practice, tirzepatide led to a mean 18.04 kg (17.21%) weight loss over six months. More than 95% of participants lost at least 5% of their body weight, and about 60% lost at least 15%, with improvements in metabolic measures and quality of life and a low dropout rate.
Journal article — Prospective longitudinal observational study. Population: Adults with BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity in real-world practice. Sample size: 107 participants. Follow-up: 6 months. Interventions: tirzepatide.
After 6 months, the mean body weight reduction was 18.04 kg, representing a 17.21% decrease from baseline. A total of 95.35% of participants achieved at least 5% weight loss, and 60.47% achieved at least 15%. The median tirzepatide dose at 6 months was 7.5 mg. Significant improvements were observed in glycaemic and lipid profiles, with enhancements in health-related quality of life and a favourable tolerability profile. The dropout rate was 3.7%.
This paper provides real-world evidence on tirzepatide for obesity, complementing randomised controlled trial findings. It demonstrates substantial weight loss and metabolic improvements at a median maintenance dose of 7.5 mg, with a low dropout rate. It does not establish long-term safety or efficacy beyond 6 months, nor does it compare tirzepatide with other weight-management interventions.
Peptide profiles: Tirzepatide.
All indexed evidence: Tirzepatide trials & papers.
Related studies: Peripheral nerve complications from medications utilised for weight loss: a systematic…, Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of…, Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory…, Comparative effects of drugs for adults with overweight or obesity: systematic review….